Showing: 1 - 3 of 3 RESULTS

Tyme Technologies to Present at Jefferies Virtual Global Healthcare Conference on November 17-19, 2020

Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership will present at the Jefferies Virtual Global Healthcare Conference on November 17-19. In one-on-one sessions, the Company will present its corporate overview for fiscal year 2021 with a special focus on multiple growth opportunities driven by advances in the science of cancer cell metabolism, SM-88 (racemetyrosine) late-stage trials in pancreatic cancer, SM-88 HopES trial in ultra-rare metastatic sarcoma, proof-of-concept RESPOnD™ trial evaluating TYME-19 in COVID-19, and expanding clinical plans for its cancer-metabolism pipeline candidate SM-88 in prostate, breast and hematological cancers.

Event: Jefferies Virtual Global Healthcare Conference
Place: Waldorf Hilton, London
Presentation Date: November 17-19, 2020
Format: One-on-one sessions

The presentation will be accessible on the events page under the investor relations section of Tyme Technologies’ website at www.tymeinc.com.

About SM-88

SM-88 is an oral investigational modified proprietary tyrosine derivative that is believed to interrupt the metabolic processes of cancer cells by breaking down the cells’ key defenses and leading to cell death through oxidative stress and exposure to the body’s natural immune system. Clinical trial data have shown that SM-88 has demonstrated encouraging tumor responses across 15 different cancers, including pancreatic, lung, breast, prostate and sarcoma cancers with minimal serious grade 3 or higher adverse events. Learn more.

About TYME-18

TYME-18 is composed of a proprietary surfactant delivery agent with a specific sulfonic acid component. It is designed for intra-tumoral administration of difficult to treat tumors and leverages the acidic tumor microenvironment and signaling pathways to kill cancer cells. TYME-18 is distinct in composition, but like SM-88, aims to leverage susceptibilities of a cancer that are related to its altered metabolism. Initial preclinical data for TYME-18 in animal tumor models demonstrate rapid and complete tumor regression, with no reported local or systemic toxicities. TYME-18 continues to be studied as a potential therapy for difficult to treat tumors that may not be eligible for surgical or other interventions. Learn more.

About TYME-19

TYME-19 is a potent, well characterized synthetic antiviral bile acid that is being evaluated as a potential oral therapy for COVID-19. In preclinical testing, TYME-19 repeatedly prevented COVID-19 viral replication without attributable cytotoxicity in treated cells. COVID-19 hijacks a cell’s ability to make proteins and lipids and divert these processes to make viral proteins and lipids in order to reproduce. COVID-19 accomplishes this by inducing stress in the endoplasmic reticulum (ER), where cells process proteins, which enables the virus to remodel protein and lipid synthesis. In preclinical testing, TYME-19 has been shown to counteract these effects, preventing viral replication, by reducing ER stress. TYME-19 is believed to physically degrade viruses by solubilizing the protective lipid layer and other structural components, which prevent a virus from binding to and infecting a cell.

About TYME-88-Panc Pivotal Trial

The TYME-88-Panc pivotal trial applies the latest advances in the field of cancer metabolism by evaluating the efficacy and safety of an oral investigational compound that targets the metabolic mechanisms of the

Euro NCAP begins testing driver-assist technologies

The European New Car Assessment Programme (Euro NCAP) is launching a new set of safety tests designed to evaluate driver assistance systems. Aside from seeing how well these systems function, the new tests are also designed give consumers a better understanding of driver assists with different names and functionalities, by fitting them in neat categories.

Euro NCAP’s new assessment protocols focus on three key main areas: Assistance Competence for how well the systems work, Vehicle Assistance for the extent to which it keeps the driver alert and engaged (Driver Engagement) – and Safety Backup, for the system’s effectiveness in critical situations.

Some of the driver assistance systems that will be tested include Highway Assist (HA), a technology designed to make motorway driving safer by reducing fatigue and encouraging safe driving. Adaptive Cruise Control (ACC), and Lane Centering (LC) equipment will also be tested.

https://www.euroncap.com/
https://www.euroncap.com/

The tests will involve a grading scheme with Very good, Good, Moderate, or Entry ratings. These won’t necessarily affect a car’s overall Euro NCAP star rating. However, they will let car buyers know the effectiveness of these systems and the accuracy of how they are marketed.

The first set of vehicles have already been tested, with the latest test series including ten cars that offer Highway Assist: the Audi Q8, BMW 3 Series, Ford Kuga, the Mercedes GLE-Class, Nissan Juke, Peugeot 2008, Renault Clio, Tesla Model 3, Volkswagen Passat, and Volvo V60.

Among those tested, the Mercedes GLE earned the highest ratings (174 out of 200), with Euro NCAP evaluators noting its ability to keep the “driver engaged with plenty of clear communication regarding the assistance offered.” Not too far behind is the BMW 3 Series (172 out of 200), thanks to its intuitive system, with the Audi Q8 getting the third-best score (162 out of 200). All three of those cars received a ‘Very good’ grading.

https://www.euroncap.com/
https://www.euroncap.com/

“Assisted driving technologies offer enormous benefits by reducing fatigue and encouraging safe driving,” said Dr. Michiel van Ratingen, Euro NCAP Secretary General. “However, manufacturers must ensure that assisted driving technology does not increase the amount of harm incurred by drivers or other road users compared to conventional driving.”

“The results of this round of tests demonstrate that driving assistance is fast becoming better and more readily available, but until driver monitoring is significantly improved, the driver needs to remain responsible at all times,” van Ratingen added.

Photo/s from Euro NCAP

Also read:

2nd-Gen Nissan Juke Secures 5-Star Safety Rating from Euro NCAP

Why Don’t Luxury Cars Have NCAP Safety Ratings?

Source Article

Schwazze, Formerly Operating as Medicine Man Technologies, Inc., Provides Update on Acquisition Strategy

DENVER–(BUSINESS WIRE)–Sep 30, 2020–

Schwazze, formerly operating as Medicine Man Technologies Inc. (OTCQX: SHWZ) (“Schwazze ” or “the Company”), a leading vertically-integrated Colorado cannabis company, today provided an update on its acquisition strategy.

The Company announced the termination of previously named term sheet with MedPharm Holdings, a cannabis research and development operator, which expired today, September 30, 2020. As noted earlier this year, the Company had moved forward on numerous term sheets with Colorado cannabis operators but had completed limited due diligence at that time. After the rigorous review and vetting process of MedPharm, the Company was unable to reach a mutually beneficial agreement to acquire MedPharm.

Justin Dye, Chairman and Chief Executive Officer of Schwazze shared, “The decision to terminate the binding term sheet with MedPharm is the right step forward for Schwazze. We are committed to creating shareholder value and generating compelling investment returns and believe that by staying true to our core business strategy of building a vertically integrated platform, we will do just that. Our focus remains unchanged, as our intention is to bring together profitable cannabis operators while growing organically to create a robust, differentiated and most admired cannabis company.”

Schwazze reiterated its commitment to establishing a leading vertically integrated cannabis platform. To accomplish this, the Company has acquired Mesa Organics, a dispensary chain with four locations in Southern Colorado, Purplebee’s a leading extraction and manufacturing business and remains on track to acquire the 14 Colorado locations of Star Buds which includes 13 retail locations and a cultivation facility. The Company will continue to make decisions that uniquely position Schwazze to provide the most trusted products and experiences for consumers and the best value for shareholders. The Company remains in negotiations with the announced acquisitions Roots Rx and Canyon Cultivation.

For more information about Schwazze, please visit https://www.Schwazze.com/.

About Schwazze

Medicine Man Technologies, Inc. is now operating under its new trade name, Schwazze. Schwazze (OTCQX: SHWZ) is executing its vision to become a leading vertically integrated cannabis holding company with a portfolio consisting of top-tier licensed brands spanning cultivation, extraction, infused-product manufacturing, dispensary operations, consulting, and a nutrient line. Schwazze leadership includes Colorado cannabis leaders with proven expertise in product and business development as well as top-tier executives from Fortune 500 companies. As a leading platform for vertical integration, Schwazze is strengthening the operational efficiency of the cannabis industry in Colorado and beyond, promoting sustainable growth and increased access to capital, while delivering best-quality service and products to the end consumer. The corporate entity continues to be named Medicine Man Technologies, Inc.

Forward-Looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual